MA54923A - Traitement de l'amylose al avec la combinaison d'anticorps monoclonaux dirigés contre des chaînes légères d'immunoglobuline et de la molécule de membrane cellulaire cd38 sur des cellules productrices d'anticorps et d'autres cellules immunitaires - Google Patents
Traitement de l'amylose al avec la combinaison d'anticorps monoclonaux dirigés contre des chaînes légères d'immunoglobuline et de la molécule de membrane cellulaire cd38 sur des cellules productrices d'anticorps et d'autres cellules immunitairesInfo
- Publication number
- MA54923A MA54923A MA054923A MA54923A MA54923A MA 54923 A MA54923 A MA 54923A MA 054923 A MA054923 A MA 054923A MA 54923 A MA54923 A MA 54923A MA 54923 A MA54923 A MA 54923A
- Authority
- MA
- Morocco
- Prior art keywords
- amylodis
- antibody
- treatment
- combination
- monoclonal antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804721P | 2019-02-12 | 2019-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54923A true MA54923A (fr) | 2021-12-22 |
Family
ID=69182616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054923A MA54923A (fr) | 2019-02-12 | 2019-12-16 | Traitement de l'amylose al avec la combinaison d'anticorps monoclonaux dirigés contre des chaînes légères d'immunoglobuline et de la molécule de membrane cellulaire cd38 sur des cellules productrices d'anticorps et d'autres cellules immunitaires |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220213223A1 (fr) |
| EP (1) | EP3923954A1 (fr) |
| JP (1) | JP2022520572A (fr) |
| KR (1) | KR20210143752A (fr) |
| CN (1) | CN113924099A (fr) |
| AU (1) | AU2019429147A1 (fr) |
| BR (1) | BR112021015870A2 (fr) |
| CA (1) | CA3129890A1 (fr) |
| CL (1) | CL2021002140A1 (fr) |
| EA (1) | EA202192235A1 (fr) |
| IL (1) | IL285480A (fr) |
| JO (1) | JOP20210220A1 (fr) |
| MA (1) | MA54923A (fr) |
| MX (1) | MX2021009687A (fr) |
| SG (1) | SG11202108767PA (fr) |
| WO (1) | WO2020167376A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113811332A (zh) | 2019-03-05 | 2021-12-17 | 普罗塞纳生物科学有限公司 | 治疗al淀粉样变性的方法 |
| TW202216760A (zh) | 2020-07-23 | 2022-05-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | 抗類澱粉β (ABETA)抗體 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| SI2511297T1 (sl) | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
| RS59399B1 (sr) | 2005-03-23 | 2019-11-29 | Genmab As | Antitela protiv cd38 za lečenje multiplog mijeloma |
| EA036059B1 (ru) | 2007-12-28 | 2020-09-21 | Протена Байосайенсиз Лимитед | Способ получения антитела или его фрагмента, которое специфически связывается с агрегированным амилоидным белком |
| DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| KR102196009B1 (ko) * | 2011-10-25 | 2021-01-04 | 프로테나 바이오사이언시즈 리미티드 | 항체 제형 및 방법 |
| EP2771033A4 (fr) | 2011-10-28 | 2016-02-17 | Integritybio Inc | Formulations protéiques contenant des acides aminés |
| EP4219561A3 (fr) * | 2015-05-20 | 2023-11-08 | Janssen Biotech, Inc. | Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaîne légère et d'autres tumeurs malignes hématologiques positives à cd38 |
| MA43187B1 (fr) | 2015-11-03 | 2021-02-26 | Janssen Biotech Inc | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations |
| HRP20220979T8 (hr) * | 2016-06-30 | 2023-02-03 | Prothena Biosciences Limited | Sastavi za liječenje amiloidoze |
-
2019
- 2019-12-16 SG SG11202108767PA patent/SG11202108767PA/en unknown
- 2019-12-16 AU AU2019429147A patent/AU2019429147A1/en active Pending
- 2019-12-16 EP EP19839484.3A patent/EP3923954A1/fr active Pending
- 2019-12-16 MX MX2021009687A patent/MX2021009687A/es unknown
- 2019-12-16 JO JOP/2021/0220A patent/JOP20210220A1/ar unknown
- 2019-12-16 JP JP2021547075A patent/JP2022520572A/ja active Pending
- 2019-12-16 WO PCT/US2019/066648 patent/WO2020167376A1/fr active Application Filing
- 2019-12-16 EA EA202192235A patent/EA202192235A1/ru unknown
- 2019-12-16 CA CA3129890A patent/CA3129890A1/fr active Pending
- 2019-12-16 KR KR1020217029118A patent/KR20210143752A/ko unknown
- 2019-12-16 CN CN201980094744.5A patent/CN113924099A/zh active Pending
- 2019-12-16 US US17/429,876 patent/US20220213223A1/en active Pending
- 2019-12-16 BR BR112021015870A patent/BR112021015870A2/pt unknown
- 2019-12-16 MA MA054923A patent/MA54923A/fr unknown
-
2021
- 2021-08-09 IL IL285480A patent/IL285480A/en unknown
- 2021-08-12 CL CL2021002140A patent/CL2021002140A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3129890A1 (fr) | 2020-08-20 |
| CL2021002140A1 (es) | 2022-04-18 |
| EP3923954A1 (fr) | 2021-12-22 |
| EA202192235A1 (ru) | 2022-01-19 |
| CN113924099A (zh) | 2022-01-11 |
| KR20210143752A (ko) | 2021-11-29 |
| IL285480A (en) | 2021-09-30 |
| AU2019429147A1 (en) | 2021-09-09 |
| MX2021009687A (es) | 2021-12-10 |
| SG11202108767PA (en) | 2021-09-29 |
| US20220213223A1 (en) | 2022-07-07 |
| WO2020167376A8 (fr) | 2020-10-29 |
| JP2022520572A (ja) | 2022-03-31 |
| BR112021015870A2 (pt) | 2021-11-03 |
| JOP20210220A1 (ar) | 2023-01-30 |
| WO2020167376A1 (fr) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54923A (fr) | Traitement de l'amylose al avec la combinaison d'anticorps monoclonaux dirigés contre des chaînes légères d'immunoglobuline et de la molécule de membrane cellulaire cd38 sur des cellules productrices d'anticorps et d'autres cellules immunitaires | |
| MA43368A (fr) | Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales | |
| CO6231000A2 (es) | Anticuerpos contra de erbb3 y usos de los mismos | |
| MA32126B1 (fr) | Anticorps et immunoconjugués anti-cd79b et leurs procédés d'utilisation | |
| EA202190608A1 (ru) | Однодоменные анти-bcma антитела и их применение | |
| EA201000274A1 (ru) | Антитела к cd37 | |
| RU2008139602A (ru) | Гуманизированное моноклональное анти-cd20-антитело | |
| MY159013A (en) | Recombinant protein production in avian ebx® cells | |
| RS53984B1 (en) | IP-10 ANTIBODIES AND THEIR USES | |
| DE3580654D1 (de) | Menschlicher hybridomfusionspartner zur herstellung menschlicher monoklonaler antikoerper. | |
| CO6150200A2 (es) | Anticuerpos anti-notch1 nrr y sus metodos de uso | |
| MA32566B1 (fr) | Anticorps neutralisant les cytomégalovirus humains et leurs utilisations | |
| DE69721713D1 (de) | Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag) | |
| ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
| AR084263A1 (es) | Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) | |
| FR3065473B1 (fr) | Panneau pour le traitement acoustique comprenant des alveoles contenant chacune une pluralite de conduits | |
| BR112022026508A2 (pt) | Anticorpos que reconhecem sortilina | |
| MA55797A (fr) | Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19 | |
| CY1108473T1 (el) | Διαγονιδιακοι ποντικοι χρησιμοποιουμενοι ως προτυπο για ανθρωπινες παθησεις οφειλομενες σε βλαστοκυτταρα | |
| ATE556094T1 (de) | Rohre für den transport von chloramin enthaltendem wasser | |
| DE60141832D1 (de) | Humaner monoklonaler antikörper gegen das hepatitis c virus e2 glykoprotein | |
| Bayona-i-Carrasco et al. | Movilidad residencial en edades avanzadas en España: Una perspectiva metropolitana | |
| MX2023013714A (es) | Anticuerpos anti-proteina accesoria del receptor de interleucina 1 (il-1). | |
| Tretyakova | OA Novikova-«unofficial ambassador» of Russia in England | |
| JP1735183S (ja) | 連結部材 |